Developing a recognition system for acromegaly

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to compare the 3D stereophotography features of patients with acromegaly to those of healthy individuals. By analyzing these differences, the researchers hope to create a computerized model that can assist in the early detection and screening of acromegaly. Given the slow progression of the disease and the challenges in current diagnostic methods, this approach could provide a more accessible and cost-effective solution for identifying patients at risk. The study will include both acromegaly patients and healthy adults aged 20 to 80 years.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 20-80 years old, Acromegaly patients or Healthy Adults

Exclusion Criteria:

* Pregnancy. Age less than 20 years old or older than 80 years old

Where it's running

• National Taiwan University Hospital
  Taipei, Taiwan Recruiting

Study contacts

• Principal investigator: Shyang-Rong Shih, PhD — National Taiwan University Hospital
• Study coordinator: Shyang-Rong Shih, PhD
• Email: srshih@ntu.edu.tw
• Phone: 886-2-23123456

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NTQ6179 tablets first-in-human test in healthy adults

  This phase 1 study tests a single oral dose of NTQ6179 vs placebo in healthy adults to see if it is safe and how the body processes the drug.

  Recruiting Phase 1 Nanjing Chia-tai Tianqing Pharmaceutical · Beijing · NCT07909837

• Test MAR002 for acromegaly in adults on or off medical therapy

  This study tests whether subcutaneous MAR002 is safe and tolerable in adults with acromegaly, compared with a placebo, over 10 weeks.

  Recruiting at 3 sites Phase 2 Marea Therapeutics · Phoenix, Arizona and 2 other locations · NCT07641179

• Octreotide SC Depot in Acromegaly: Real-World Safety and Effectiveness

  This study follows people with acromegaly who are using octreotide subcutaneous depot to see how it works and how safe it is over up to two years in everyday clinical practice.

  Recruiting at 4 sites Camurus AB · Aachen and 6 other locations · NCT07583563

• MAR002 in healthy men

  This trial tests whether a subcutaneous injection of MAR002 is safe and tolerable in healthy men aged 18 to 40.

  Recruiting Phase 1 Marea Therapeutics · Tempe, Arizona · NCT07195175

• Pasireotide LAR and bone health in adults with acromegaly

  This study will test whether switching adults with uncontrolled acromegaly to pasireotide LAR changes bone turnover and the risk of vertebral fractures.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, RM · NCT07179926

• Assessing Debio 4126 for treating acromegaly in patients on somatostatin analogs

  This study is testing if a new treatment called Debio 4126 can help people with acromegaly who are already on somatostatin analogs keep their IGF-1 levels in check better than a placebo.

  Recruiting at 72 sites Phase 3 Debiopharm International SA · Los Angeles, California and 73 other locations · NCT06930625

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.